AbbVie (ABBV) Tops Q1 EPS by 9c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says
April 23, 2015 11:47 AM EDTBMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV) following Q1 results. The analyst said Street Hep-C numbers need to come down although the bullish thesis is intact.
Arfaei commented, "ABBV shares are down about 2% as we prepare this note, despite the company reporting strong 1Q15 results. We believe the weakness is likely related to new Hep-C data released from Gilead (NASDAQ: GILD)."
He continued, "A Phase 2... More
